Tags

Type your tag names separated by a space and hit enter

CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Clin Transl Oncol. 2019 Feb; 21(2):167-177.CT

Abstract

PURPOSE

To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

METHODS

367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1-2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.

RESULTS

There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1-3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1-3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.

CONCLUSION

DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.

Authors+Show Affiliations

Interventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.Department of Radiology, Hangzhou Cancer Hospital, No. 34 Yan Guan lane, Hangzhou, China.Department of Liver Oncology, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo, 315010, China.Department of Hepatobiliary Surgery, Ningbo Medical Center Lihuili Easter Hospital, No. 1111 Jiangnan Road, Ningbo, 315000, China.Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.Department of Radiology, Beilun District People's Hospital of Ningbo, No. 1288 Lushang East Road, Ningbo, 315826, China.Department of Intervention, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, No. 108 Wansong Road, Ruian, 325200, China.Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Hospital of TCM, No. 54 Youdian Road, Hangzhou, 310006, China.Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's Hospital, Hengbu Street 2, Hangzhou, 310023, China.Interventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.Department of Intervention, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310000, China.Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Lishui, 323000, China.Department of Intervention, Jiaxing Second Hospital, No. 1518 Huangcheng North Road, Jiaxing, 314000, China.Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.Interventional Center, Xinchang People's Hospital, No. 117 Gushan Road, Xinchang, 312500, China.Department of Intervention, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, No. 365 Renmin East Road, Jinhua, 321000, China.Department of Radiology, Shulan (Hangzhou) Hospital, No. 848 Dongxin Road, Hangzhou, 310026, China.Department of Vascular and Interventional Radiology, The Affiliated Hospital of Medical School of Ningbo University, No. 247 Renmin Road, Ningbo, 315020, China.Division of Digestive Endoscopy, Yueqing City People's Hospital, No. 338 Qingyuan Road, Yueqing, 325600, China.Department of Hepatobiliary Surgery, Quzhou People's Hospital, No. 2 Zhongloudi, Quzhou, 324000, China.Interventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.Department of Intervention, The First Provincial Wenzhou Hospital of Zhejiang, The First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325099, China.Department of Radiology, Taizhou Hospital of Zhejiang Province, No. 150 Ximen Street, Linhai, 317000, China.Department of Intervention, Jiaxing First Hospital, No. 1882 Zhonghuan South Road, Jiaxing, 314001, China.Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, China.Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.Department of Intervention, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310000, China.Department of Liver Oncology, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo, 315010, China.Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, China.Department of Intervention, Dongyang People's Hospital, No. 60 Wuning West Road, Dongyang, 322100, China. 425183318@qq.com.Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China. shaoguoliang1@163.com.

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

30003530

Citation

Zhang, X, et al. "CalliSpheres® Drug-eluting Beads (DEB) Transarterial Chemoembolization (TACE) Is Equally Efficient and Safe in Liver Cancer Patients With Different Times of Previous Conventional TACE Treatments: a Result From CTILC Study." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 21, no. 2, 2019, pp. 167-177.
Zhang X, Zhou J, Zhu DD, et al. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. Clin Transl Oncol. 2019;21(2):167-177.
Zhang, X., Zhou, J., Zhu, D. D., Huang, J., Sun, J. H., Li, T. F., Shi, C. S., Sun, Z. C., Hou, Q. M., Peng, Z. Y., Yu, W. Q., Ji, J. S., Gu, W. J., Zhou, G. H., Xie, X. X., Guo, X. H., Cao, G. H., Yu, Z. H., Xu, H. H., ... Shao, G. L. (2019). CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 21(2), 167-177. https://doi.org/10.1007/s12094-018-1902-8
Zhang X, et al. CalliSpheres® Drug-eluting Beads (DEB) Transarterial Chemoembolization (TACE) Is Equally Efficient and Safe in Liver Cancer Patients With Different Times of Previous Conventional TACE Treatments: a Result From CTILC Study. Clin Transl Oncol. 2019;21(2):167-177. PubMed PMID: 30003530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. AU - Zhang,X, AU - Zhou,J, AU - Zhu,D-D, AU - Huang,J, AU - Sun,J-H, AU - Li,T-F, AU - Shi,C-S, AU - Sun,Z-C, AU - Hou,Q-M, AU - Peng,Z-Y, AU - Yu,W-Q, AU - Ji,J-S, AU - Gu,W-J, AU - Zhou,G-H, AU - Xie,X-X, AU - Guo,X-H, AU - Cao,G-H, AU - Yu,Z-H, AU - Xu,H-H, AU - Fang,J, AU - Ying,S-H, AU - Hu,W-H, AU - Ji,W-B, AU - Han,J, AU - Wu,X, AU - Zheng,J-P, AU - Luo,J, AU - Chen,Y-T, AU - Hu,T-Y, AU - Li,L, AU - Hu,H-J, AU - Du,H-J, AU - Shao,G-L, Y1 - 2018/07/12/ PY - 2017/11/04/received PY - 2018/05/24/accepted PY - 2018/7/14/pubmed PY - 2019/5/30/medline PY - 2018/7/14/entrez KW - Drug-eluting beads transarterial chemoembolization (DEB-TACE) KW - Efficacy KW - Liver cancer KW - Previous cTACE treatment KW - Safety SP - 167 EP - 177 JF - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JO - Clin Transl Oncol VL - 21 IS - 2 N2 - PURPOSE: To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments. METHODS: 367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1-2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments. RESULTS: There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1-3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1-3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups. CONCLUSION: DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments. SN - 1699-3055 UR - https://www.unboundmedicine.com/medline/citation/30003530/CalliSpheres®_drug_eluting_beads__DEB__transarterial_chemoembolization__TACE__is_equally_efficient_and_safe_in_liver_cancer_patients_with_different_times_of_previous_conventional_TACE_treatments:_a_result_from_CTILC_study_ L2 - https://dx.doi.org/10.1007/s12094-018-1902-8 DB - PRIME DP - Unbound Medicine ER -